Parallel Advisors’s Prelude Therapeutics PRLD Stock Holding History

Parallel Advisors’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-38	Closed	-$618	–	3247
2021 Q3	$1K	Buy	38 +6	+19%	+$194	﹤0.01%	2934
2021 Q2	$1K	Buy	+32	New	+$1.14K	﹤0.01%	2803

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parallel Advisors's PRLD Position: Q4 2021 in Review

Parallel Advisors sold out of Prelude Therapeutics (PRLD) in Q4 2021, closing a stake of 38 shares — an estimated $618 sold.

Parallel Advisors first reported a position in PRLD in Q2 2021 and held it in 2 quarters. The position peaked at $1K in Q3 2021. 75 funds tracked by Wall St. Rank hold PRLD as of Q4 2021.

Parallel Advisors reported no remaining Prelude Therapeutics position as of Q4 2021 after selling out during the quarter.
Parallel Advisors sold 38 Prelude Therapeutics shares in Q4 2021, an estimated $618.
Parallel Advisors first reported a position in Prelude Therapeutics in Q2 2021 and held it in 2 quarters.
Parallel Advisors's Prelude Therapeutics position peaked at $1K in Q3 2021.
75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2021.

Based on Parallel Advisors's 13F filing for Q4 2021, filed 20 Jan 2022.